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In our initial studies we found that nave CCR6-deficient (CCR6–/–) C57BL/6 mice
possessed significantly lower number of both F4/80+ macrophages and dendritic cells
(DC), but higher number of B cells in the peritoneal cavity, as compared to nave wild
type (WT) controls. Furthermore, peritoneal macrophages isolated from CCR6–/– mice
expressed significantly lower levels of inflammatory cytokines and nitric oxide
following lipopolysaccharide (LPS)stimulation, as compared to WT macrophages. In a
severe experimental peritonitis model induced by cecal ligation and puncture (CLP),
CCR6–/– mice were protected when compared with WT controls. At 24 h following the
induction of peritonitis, CCR6–/– mice exhibited significantly lower levels of
inflammatory cytokines/chemokines in both the peritoneal cavity and blood.
Interestingly, DC recruitment into the peritoneal cavity was impaired in CCR6–/– mice
during the evolution of CLP-induced peritonitis. Peritoneal macrophages isolated from
surviving CCR6–/– mice 3 days after CLP-induced peritonitis exhibited an enhanced LPS
response compared with similarly treated WT peritoneal macrophages. These data
illustrate that CCR6 deficiency alters the innate response via attenuating the
hyperactive local and systemic inflammatory response during CLP-induced peritonitis.
Introduction
Despite advances in intensive care unit interventions
and the use of specific antibiotics, sepsis with con-
comitant multiple organ failure is the most common
cause of death in many acute care units. In this setting,
approximately one-third of 750 000 people annually
affected by sepsis die [1–4]. Sepsis is characterized by an
initial overwhelming systemic inflammatory response
syndrome (SIRS) (also known as a cytokine storm),
which is followed by a compensatory anti-inflammatory
response syndromes (CARS) [5]. Innate immune cells,
including macrophage, PMN and DC are the main
inflammatory cell types responsible for excessive
cytokine production during the evolution of this
response. These cells both produce and respond to
proinflammatory cytokines and chemokines, suggesting
that they might be appropriate targets for the treatment
of severe sepsis. A number of novel therapeutics,
specifically developed to prevent sepsis-induced mor-
tality have failed, with the exception of recombinant
activated protein C [6], supporting the concept that
severe sepsis is dynamic and complex disease.
Chemokines are a family of structurally related
chemotactic proteins, whose functions have been well
studied on many fundamental aspects of immunology,
including the development, homeostasis and host
inflammatory response. The effects of specific chemo-
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kines/chemokine receptors in the initiation and the
progression of severe experimental sepsis have been
previously reported, due to divergent and varied
mechanisms [7–13]. However, the role of CCR6 in
severe sepsis has not been previously investigated.
Interestingly, unlike most of the chemokine family
members, CCR6 has only one chemokine ligand, CCL20,
although b-defensin has been reported to bind CCR6
with a lower affinity [14]. CCR6 has been shown to be
expressed on immature DC [15–17], memory Tcells [18]
andB cells [19], suggesting that CCR6plays an important
role in adaptive immunity. This notion is further
exemplified by CCR6/CCL20-dependent immature DC
migration, which is an essential mechanism for CD8+
T cell activation and host immunity against invasive
pathogens in the skin and GI tract, respectively [20, 21].
CCR6/CCL20 has also been reported to be involved in
lymphocyte-mediated chronic inflammation, such as
asthma [17] and chronic obstructive pulmonary disease
(COPD) [22]. Little is known about the role of CCR6 in
innate immunity, except that CCL20 has been shown to
direct the recruitment of NK cells [23].
The aim of the present study is to evaluate the
contribution of CCR6 to the systemic inflammatory
response and in vivo outcome in an experimental sepsis
model induced by cecal ligation and puncture (CLP). We
demonstrate that the deficiency in CCR6 (CCR6–/–)
alters peritoneal cellularity in nave mice and renders
mice resistance to CLP-induced mortality. In the latter
situation, the absence of CCR6 was associated with
dramatically lower peritoneal and systemic cytokine
levels. The number of DC was significantly decreased in
nave CCR6–/– mice and the recruitment of DC was
impaired during severe sepsis, supporting the concept
that CCR6 is involved in DC recruitment to inflamma-
tory sites. Furthermore, CCR6–/– peritoneal macro-
phages show an attenuated response to TLR agonist
stimulation compared with similarly treated WTcontrol.
The latter information may provide the mechanism for
the lower levels of inflammatory cytokines and the
survival advantage in CCR6–/– mice. Thus, this study
demonstrates that CCR6 deficiency modulates the initial
local immune response and alters subsequent inflam-
matory cascades normally associated with systemic
immune reactivity.
Results
Depletion of CCR6 alters inflammatory cell
populations in nave mice
Given that CCR6 have been reported to regulate the
normal DC localization in Peyer's patches [24, 25], we
tested whether the depletion of CCR6 altered the
localization of resident cell populations in the peritoneal
cavity of nave mice. Flow cytometric analysis was used
to compare the numbers of several resident peritoneal
cell types between WT C57BL/6 (CCR6+/+) and
C57BL/6 CCR6–/– mice. Whereas there was no differ-
ence in the number of total peritoneal cells between two
groups, we found CCR6–/– mice had significant fewer
CD11b+F4/80+ macrophages (50.4  7.7  104 vs. 72.4
 8.4 10 4/per mouse, n= 5) and CD11c+MHCII+ DC
(0.8  0.1  104 vs. 1.5  0.2  10 4/per mouse, n = 5)
compared with WTcontrols (Table 1). In contrast, there
were significantly more CD19+ B cells in the peritoneal
cavities of CCR6–/– mice compared with controls (1.5 
0.25  106 vs. 1.2  0.3  10 6/per mouse, n = 5)
(Table 1). No difference was found in the number of
peritoneal CD4+ and CD8+ T cells, as well as NK cells
between the CCR6–/– and WT groups. Therefore, CCR6
depletion alters the normal composition of peritoneal
cells and results in a decrease in the cell types of myeloid
origin, but an increase in B cell number.
Nave CCR6–/– peritoneal macrophages display an
attenuated LPS-response
Macrophages are major participants in innate immunity,
because of their ability to phagocytose pathogens,
generate cytotoxic oxygen and nitrogen intermediates,
and express chemokines and cytokines that either attract
or activate other immune cells. However, the over-
production of inflammatory factors during host defense
leads to serious deleterious effects in normal tissues if
left uncontrolled. We next sought to determine whether
the presence of CCR6 affected the production of
peritoneal macrophage-derived inflammatory media-
tors. Peritoneal macrophages from WT and CCR6–/–
mice were harvested by peritoneal lavage and stimulated
with 1 lg/mL LPS. After 4 h, CCR6–/– peritoneal
macrophages contained significantly lower mRNA levels
of IL-12p35, IL-12p40, IL-10, TNF-a, CCL2, CCL3 and
CXCL10 (Fig. 1A). Furthermore, after 24 h of stimula-
Table 1. Peritoneal leukocyte subsets in nave micea)
Group CCR6+/+ CCR6–/–
Total cells 293.5  46 305.5  48.8
CD11b+ F4/80+b) 72.4  8.4 50.4  7.7
CD19+b) 115.5  27.6 151.6  25.4
CD4+ 15.3  0.4 18.7  0.4
CD8+ 4.8  0.3 5.9  0.3
NK1.1+ 3.1  0.4 2.7  0.4
CD11c+ MHCII+b) 1.5  0.2 0.8  0.1
a) All values are (104)/per mouse.
b) Significant difference between the two groups.
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tion with LPS, CCR6–/– peritoneal macrophages pro-
duced significantly lower protein levels of IL-12p70,
IL-10, TNF-a, CCL2, CCL3 and CXCL10 (Fig. 1B), which
is consistent with their mRNA levels after 4 h of LPS
stimulation.
Nave CCR6–/– peritoneal macrophages were also
assessed for the levels of nitrite, which reflect the
expression of NO, one of the major macrophage-derived
effector molecules that is cytotoxic [26] and can induce
host tissue injury [27]. Peritoneal macrophages isolated
from CCR6–/– mice generated significantly lower level of
nitrite in response to either a 100 ng/mL LPS challenge
(3.7  1.0 vs. 8.3  1.1 lM, n = 5), or challenged with
LPS plus 20 U/mL IFN-c (4.7  0.98 vs. 15.3  2.2 lM,
n = 5), respectively, as compared to WT peritoneal
macrophages (Fig. 1C). Collectively, our data indicated
that the absence of CCR6 resulted in an attenuated LPS-
response by nave peritoneal macrophages.
Previously, our group has shown that CCR4–/–
peritoneal macrophages exhibited a constitutive phe-
notype of alternative activation. Since we observed that
CCR6–/– peritoneal macrophages showed an attenuated
LPS response, we further tested if CCR6–/–macrophages
were also skewed to alternative activation status.
Alternative activated macrophages has been tightly
linked to the up-regulation of several molecules,
including mannose receptor (MR), arginase 1 and the
found in inflammatory zone 1 (FIZZ1) [28]. There was
no difference in mRNA levels of MR, arginase 1 and
FIZZ1 between CCR6–/– and WT peritoneal macro-
phages in response to either medium alone or LPS
(Fig.1D). BothWTand CCR6–/– peritoneal macrophages
generated similar amount of FIZZ1 protein in in vitro
culture system (Fig. 1E). These data suggest that
CCR6–/– peritoneal macrophages are not skewed to
alternative activation.
Figure 1. Cytokine production by
peritoneal macrophages from nave
WT and CCR6–/– mice. Peritoneal
macrophages were collected by peri-
toneal lavage and stimulated with
1 lg/mL LPS. Messenger RNA levels
(A) and protein production (B) of
inflammatory cytokines were mea-
sured by Taqman and ELISA, respec-
tively. (C) Nitrite production wasmea-
sured following the activation of
peritoneal macrophages with 20 U/
mL IFN-c, 100 ng/mL LPS, or both
IFN-c and LPS. (D) Messenger RNA
levels of mannose receptor, FIZZ1 and
arginase 1weremeasured by Taqman.
(E) Protein level of FIZZ1 was mea-
sured by ELISA. The results shown are
representative of five experiments
and are expressed as mean  SEM.
* p 0.05 compared with cytokine
levels measured in WT peritoneal
macrophages, n = 5.
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CCR6–/– mice are resistant to CLP-induced
peritonitis
The difference in LPS response betweenWTand CCR6–/–
peritoneal macrophages prompted us to test the role of
CCR6 in an experimental model of severe sepsis induced
by CLP. In initial studies, 100% mortality was observed
in WT mice without antibiotic treatment as early as
3 days post-CLP (Fig. 2A). However, CCR6–/– mice were
significantly protected from CLP-induced lethality (p =
0.011), and showed a 25% mortality rate at day 2 and
38%mortality rate at day 6; these latter mice were long-
term survivors. Clearly, the absence of CCR6 provided a
survival benefit compared with CCR6 competent mice.
Antibiotic treatment for 3 days following CLP attenu-
ated the severity of CLP and increased survival rates both
in the WT and CCR6–/– groups (Fig. 2B). However,
CCR6–/– mice were more resistant to CLP-induced
mortality compared to WT controls (p = 0.001).
Specifically, none of CCR6–/– mice died at day 3 after
CLP. At day 6 after CLP, 88% of the CCR6–/– mice were
alive compared with 25% of the WT mice at this time.
CCR6–/– mice express an attenuated cytokine
profile after CLP-induced peritonitis
The polymicrobial peritonitis induced by CLP is
associated with an amplified inflammatory response,
in which the local and systemic expression of many
cytokines and chemokines are augmented [29]. We
compared the cytokine profiles in peritoneal lavage fluid
and blood between WT and CCR6–/– mice before and
after CLP-induced peritonitis. Compared to WT mice,
CCR6–/– mice produced a similar amount of inflamma-
tory cytokines, including IL-12p70, IL-10, TNF-a, KC,
CCL2, CCL3 and CXCL10 in peritoneal cavity and blood
at 4 h after surgery. However, CCR6–/– mice showed
significantly lower levels of inflammatory cytokines both
Figure 2. Survival study during CLP-induced severe sepsis. WT
and CCR6–/– mice were subjected to CLP surgery, either in the
absence (A) or in presence (B) of antibiotics treatment. Survival
was monitored for 6 days following surgery. Each group: n = 10
Figure 3. Cytokines profile in WT and
CCR6–/– mice following CLP operation.
To compare the production of inflam-
matory cytokines in peritoneal cav-
ities (A) and blood (B) betweenWTand
CCR6–/– mice after CLP, ELISA was
performed to measured protein levels
of IL-12p70, IL-10, TNF-a, KC, CCL2,
CCL3 and CxCl10 in peritoneal lavage
fluid and serum. * p 0.05 compared
with cytokineprotein levelsmeasured
in WT mice 24 h after CLP, n = 5. The
results shown are representative of
three individual experiments.
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in the peritoneal cavity (Fig. 3A) and in blood (Fig. 3B)
at 24 h after CLP-induced peritonitis. We also observed
that CCR6–/– mice had significantly lower levels of
inflammatory cytokines in both the lungs and livers, as
compared to WT controls (data not shown).
Leukocyte recruitment into the peritoneal cavity
post CLP-induced peritonitis
Based on the observation that CCR6–/– displayed a
decreased cytokine production in mice, we designed a
set of investigations to determine if the alterations were
due to changes in leukocyte recruitment into the
peritoneal cavity following CLP-induced peritonitis.
Two methods were used to assess leukocyte peritoneal
infiltration in WT and CCR6–/– mice at various times
after CLP (Fig. 4). Cytospins were prepared and the
leukocyte composition, including PMN and mononuc-
lear cells, was determined by microscopic differential
counting. No difference in total numbers of leukocytes
(Fig. 4A), mononuclear cells (Fig. 4B) and PMN
(Fig. 4C) in the peritoneal cavity was observed between
the two groups of mice after CLP-induced peritonitis.
Our earlier observations demonstrated a difference in
cellular composition in the peritoneal cavity between
nave WT and CCR6–/– mice and other investigations
showed alterations in the recruitment of immature DC
during inflammatory responses [20, 21]. Thus, we
investigated changes in DC population in CCR6–/– mice
and found significantly less MHCII+CD11c+ DC in the
peritoneal cavity before and 4 and 24 h after CLP-
induced peritonitis, as compared to WT mice (Fig. 4D).
However, no difference was observed in the number of
CD11b+F4/80+macrophage (data not shown).
CCL20 shows no effect on peritoneal
macrophages and CLP-induced mortality
CCL20, the only chemokine ligand for CCR6, is up-
regulated during inflammation [30, 31] and by specific
proinflammatory cytokines [32]. An increase in CCL20
level in the peritoneal cavity was observed in WT mice
with CLP-induced peritonitis with a peak at 24 h
(Fig. 5A). CCR6–/– mice showed a significantly lower
level of CCL20 in the peritoneal cavity 24 h after CLP-
induced peritonitis, as compared toWTmice, which was
consistent with other inflammatory cytokines. This
might be due to an attenuated inflammatory response
in CCR6–/– mice. We next sought to determine whether
the presence of CCL20 exacerbated the dysregulated
immune response and promoted CLP-induced mortality
in WT mice. When endogenous CCL20 was passively
neutralized with anti-CCL20 2 h prior to CLP-induced
peritonitis and each following day, survival was not
altered, as compared to mice treated with IgG control
(Fig. 5B). These data suggested that the interaction
between CCL20 and CCR6 was not involved in the
survival of CCR6–/– mice after CLP-induced peritonitis.
We also tested whether CCL20 altered the LPS response
of WT peritoneal macrophages. LPS induced inflamma-
tory cytokine production by WT peritoneal macro-
phages, which was not altered by the presence of CCL20
in either lower (1 ng/mL) or high (100 ng/mL)
concentrations (Fig. 5C).
CCR6–/– macrophages show enhanced LPS-
responsiveness after CLP-induced peritonitis
It has been well established that macrophages develop
an unresponsiveness to LPS challenge after LPS
pretreatment, a process referred to as endotoxin
tolerance [33]. The mechanism for this tolerance
response is not fully clear. Since we observed that
CCR6–/– mice had an attenuated inflammatory immune
response and higher survival rate during CLP-induced
severe sepsis, we investigated whether the septic
response induced LPS tolerance in CCR6–/– peritoneal
macrophages. We initially focused on cytokine produc-
Figure 4. Leukocyte recruitment into peritoneal cavity in WT
and CCR6–/– mice during CLP-induced sepsis. WT and CCR6–/–
mice (n = 5/group/time point) were sacrificed at 4 h, days 1 and
3 after CLP surgery. Nave mice were used as baseline values.
Peritoneal lavage was performed to collect total peritoneal
cells. (A) Total peritoneal cell numbersweredeterminedusing a
hemocytometer. (B, C) Cytospins were prepared. The absolute
numbers of mononuclear cells and PMN were determined by
multiplying the percentage of cells by the total cell count. (D)
Peritoneal cells were stained with PE-anti-I-Ab in combination
with FITC-anti-CD11c, followed by flow cytometry analysis.
The results shown are representative of two experiments and
are expressed as mean  SEM. * p 0.05 compared with the
number ofMHCII+CD11c+ DC in peritoneal cavity ofWTmice in
nave status, or 4 and 24 h after CLP.
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tion in response to LPS stimulation. Three days after
CLP, the levels of inflammatory cytokines generally
decreased to the base line, indicating the end of the
acute phase of severe sepsis. In contrast to nave
macrophages, CCR6–/– peritoneal macrophages, at
day 3 after CLP-induced peritonitis, had significantly
higher LPS-induced mRNA levels of IL-12p35, IL-12p40,
IL-10, TNF-a, CCL3 and CXCL10, but lower CCL2 mRNA
level compared with WT peritoneal macrophages
isolated at the same time after CLP (Fig. 6A). Con-
sistently, after 24 h of stimulation with LPS, CCR6–/–
peritoneal macrophages produced significantly higher
protein levels of IL-12p70, IL-10, TNF-a, CCL3 and
CXCL10, but less CCL2 (Fig. 6B). These data suggest that
CCR6–/– peritoneal macrophages do not exhibit severe
sepsis-induced tolerance.
To test if the greater LPS responsiveness of CCR6–/–
macrophages day 3 after CLP-induced peritonitis is an
intrinsic property of CCR6–/– macrophages, or it is
because of an attenuated cytokine storm affecting
CCR6–/– peritoneal macrophages during CLP-induced
peritonitis (Fig. 3A), we next performed a classical LPS
rechallenge experiment using ex vivo peritoneal macro-
phage isolated from nave WT and CCR6–/– mice. Nave
CCR6–/– peritoneal macrophages produced significantly
lower protein levels of IL-12p70, IL-10, TNF-a, CCL2,
CCL3 and CXCL10 in response to one-time LPS challenge
compared to similarly treated WT control, which we
have previously observed (Fig. 1). Both WTand CCR6–/–
peritoneal macrophages, which have been pretreated
with 10 ng/mL LPS, showed unresponsiveness to a
second challenge with 1 lg/mL LPS, indicating that
CCR6–/– peritoneal macrophages possessed a similar
unresponsiveness to LPS challenge after LPS pretreat-
ment as WT controls (Fig. 7).
Discussion
In the present study, the role of CCR6 during
experimental severe sepsis was investigated. We found
that mice lacking CCR6 exhibited a constitutive decrease
in resident peritoneal macrophage populations, as well
as DC numbers, as compared to WT mice. Although
cytokine production by pulmonary DC and bone
marrow–derived DC in response to TLR agonist
stimulation was comparable between WT and CCR6–/–
mice (data not shown), we observed that nave CCR6–/–
peritoneal macrophage exibited a decreased production
of inflammatory cytokines and NO in response to LPS
stimulation compared with similarly treated WT con-
trols. CCR6–/– mice were significantly protected from
CLP-induced lethality and showed an attenuated
localized and systemic inflammatory cytokine produc-
tion compared with WT mice. Surprisingly, CCL20, the
only chemokine ligand of CCR6, did not appear to play a
role in the pathology of experimental sepsis, since
localized neutralization of endogenous CCL20 had no
effect on survival in septic WTmice, and CCL20 failed to
influence the LPS responsiveness of WT peritoneal
macrophages.
Figure 5. Effects of CCL20 on CLP-
inducedmortality and LPS-response of
WT peritoneal macrophages. (A) WT
and CCR6–/– mice (n = 5/group/time
point) were subjected to CLPoperation.
Peritoneal lavage fluid was collected
fromnaveWTandCCR6–/–mice and at
4, 24, 72 h post-CLP. ELISA was per-
formed to measure CCL20 level.
* p 0.05 compared with CCL20 level
in peritoneal lavage fluid from WT
mice at 24 h post-CLP. (B) WT mice
were subjected to CLP surgery in the
presence of antibiotics treatment. En-
dogenous CCL20 was blocked by anti-
CCL20. Rat IgG1 was used as a control.
Survival was monitored for 6 days
following surgery. Each group: n = 10.
(C) Peritoneal macrophages were coll-
ected from WT mice and stimulated
with LPS in the absence or presence
with either 1 ng/mL or 100 ng/mL
recombinant murine CCL20 protein.
Twenty-four hours later, cell culture
supernatantswere collected and levels
of cytokines were measured by ELISA.
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Figure 6. Cytokine production by
peritoneal macrophages from WT
and CCR6–/– mice day 3 post-CLP.
WT and CCR6–/– mice (n = 5) were
sacrificed at day 3 after CLP surgery.
Peritoneal macrophages were col-
lected by peritoneal lavage and ex-
posed to 1 lg/mL LPS. (A) Four hours
after LPS stimulation, mRNA levels of
inflammatory cytokines in peritoneal
macrophagesweremeasured by Taq-
man. *, s p 0.05 compared with
mRNA levels of inflammatory cyto-
kines inWTperitonealmacrophages.
(B) Twenty-four hours after LPS sti-
mulation, protein levels of inflam-
matory cytokines in culture super-
natants weremeasured by ELISA. a, b
p 0.05 compared with protein levels
of inflammatory cytokines produced
by WT peritoneal macrophages.
Figure 7. LPS rechallenge of peritoneal
macrophages from nave WT and
CCR6–/–mice. Peritonealmacrophages
were collected by peritoneal lavage
and pretreated with 10 ng/mL LPS for
24 h. After two washes, these cells
were stimulated with 1 lg/mL LPS for
24 h. Supernatants were collected to
measure cytokine protein levels by
ELISA. * p 0.05 compared with cyto-
kine levels measured in WT perito-
neal macrophages, n = 5.
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Chemokines and chemokine receptors were origin-
ally described to be essential mediators directing
homeostatic cell trafficking and cellular recruitment
during inflammatory responses. However, the biological
activities of chemokines are much more than only
chemotactic factors. They are now known to play
important roles in a variety of activities including
maintenance of homeostasis, angiogenesis/angiostasis,
wound healing, tumor growth and metastasis, cellular
differentiation and activation, lymphocyte development
and trafficking, lymphoid organ development, and
influencing the type 1/type 2 balance of immune
responses [34, 35]. Monocyte/macrophage trafficking
has been shown to depend on the interactions between
chemokines and chemokine receptors. For example,
CCR2 mediated homeostatic monocyte emigration from
bone marrow into circulation, and inflammation-
induced monocyte recruitment from bone marrow to
peripheral infected tissue also required CCR2 signaling
[36]. Although it has been reported that CCR2 was not
involved in tissue entry of monocyte from the circulation
[36], new data has shown that CCR2 was necessary for
efficient monocyte recruitment from the blood into
inflamed tissue [37]. CCR2–/– mice also showed an
impaired recruitment of macrophage into the peritoneal
cavity in response to thioglycollate stimulation [38].
Thus, CCR2–/– exhibited deficientmonocyte recruitment
into inflected sites in response to a broad range of
stimuli [39, 40].
While we were not surprised to observe a decrease in
peritoneal DC population in nave status and impaired
DC recruitment in inflammatory responses in CCR6–/–
mice, which was consistent with other studies [17, 22,
24, 25], it was not predicted that the population of
peritoneal macrophages also was decreased. In contrast
to numerous reports showing monocyte/macrophage
chemotactic property of chemokines and chemokine
receptors, little is know about the influence of
chemokine signaling on monocyte/macrophage lineage
development and normal function. The chemokine
receptor CXCR4 has been reported to be expressed on
hematopoietic stem cells (HSC) and the interaction of
CXCR4 with its cognate ligand, CXCL12, was essential
for the colonization of bone marrow by HSC during
development [41]. CXCR4 was also involved in HSC
homing to bone marrow [42], as well as their survival
and proliferation [43]. Thus, it is highly possible that
chemokine signaling has a role in directing normal
hematopoiesis, including the development of monocyte/
macrophage lineage. Our data showed that CCR6
controlled the localization of macrophages and DC in
the peritoneal cavity and altered the phenotype of nave
peritoneal macrophages, suggesting that CCR6 signaling
may be involved in the development of monocyte/
macrophage lineage. However, the molecular mechan-
ism whereby CCR6 influences the development and
function of peritoneal macrophages is not clear. The
possibilities are that CCR6 functions either during the
development of monocyte/ macrophage lineage from
progenitor cells in bonemarrow, or influences migration
of monocyte/ macrophage to peripheral tissues. Thus,
the role of CCR6 in the development of monocyte/
macrophage lineage is worthy of further investigation.
A number of in vitro and in vivo studies have
underscored the importance of chemokines/chemokine
receptors in the initiation of the immune response to
sepsis, as well as a direct correlation with tissue
pathology, organ dysfunction and failure, and lethality.
Immunoneutralization of CXCR2 with specific antibody
decreased PMN recruitment and CLP-induced lethality
[13, 44]. CCR1–/– mice had accelerated cytokine
production and were protected against the deleterious
effects of sepsis, due in part to the fact that CCR1–/–
peritoneal macrophages displayed both an early and
enhanced cytokine/chemokine expression profile and
anti-bacterial response. CCR4 depletion has been shown
to protect mice from systemic challenge with either LPS
[10] or other TLR agonists, as well as protect mice
against bacterial peritonitis [9]. CCR4–/– peritoneal
macrophages were demonstrated to possess a constitu-
tive phenotype of an alternatively activated macrophage
and exhibit features associated with alternative activa-
tion, including enhanced production of type-2 cyto-
kines, CCL2, CCL17 and FIZZ1 protein [9]. CCR8–/– mice
were also resistant to CLP-induced lethality, which
mechanistically may be related to the phenotype of
CCR8–/– peritoneal macrophages. These inflammatory
cells were highly activated, exhibited enhanced bacter-
icidal activities, and generated high levels of superoxide,
lysosomal enzymes and NO in response to LPS
stimulation [8, 12]. Collectively, our data in the present
study and the above reports suggests that chemokines/
chemokine receptors have a role in the development and
maintenance of normal function of peritoneal macro-
phage, since chemokine receptor deficiencies alter the
functions of peritoneal macrophages, including cytokine
production in response to TLR agonists.
Although CCL20 is the main ligand for CCR6,
b-defensin has also been shown to bind CCR6 with a
lower affinity [14]. Defensins, a family of arginine-rich
cationic peptide, have direct antimicrobial effect and are
considered an important effector molecule in innate
immune response [45, 46]. Furthermore, defensins
were also shown to chemoattract immune cells,
including monocytes/ macrophages [47, 48], mast cells
[49] and DC [14]. This suggests that defensins
contribute either direct or indirectly to the mobilization
of host immune defense in response to pathological
infections. In the present study, we observed an
attenuated inflammatory cytokine production and
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survival advantage in CCR6–/– mice during severe sepsis,
which was not related to CCL20 function. Thus, this
finding raised the question whether b-defensin was
involved in exacerbating dysregulated immune response
and cytokine production inWTmice. Interestingly, it has
been shown that human a-defensin promoted the
expression and production of CXCL5 and CXCL8 by
bronchial epithelial cells [50] and increased the
production of TNF-a and IL-1 by monocytes [51]. Thus,
it is possible that, during CLP-induced bacterial
peritonitis, b-defensin promoted the inflammatory
cytokine production by innate immune cells, including
peritoneal macrophages and DC in a CCR6-dependent
mechanism.
In summary, we have shown that genetic depletion of
CCR6 decreased cells of myeloid origin including
macrophage and DC in peritoneal cavity. Peritoneal
macrophages from CCR6–/– generated significantly
lower amounts of inflammatory cytokines and NO
compared with similarly treated WT controls. Further-
more, CCR6 depletion increased survival rate during
CLP-induced severe sepsis, which was associatedwith an
attenuated cytokine storm, an indicator of severity of
sepsis. Thus, these data suggested that CCR6 is a key
mediator in modulating the innate inflammatory
response during a septic insult and is potential target
for immunotherapy in septic patients.
Materials and methods
Mice
Specific pathogen-free female C57BL/6 WT mice were
purchased from Taconic Farms (Germantown, NY). Female
CCR6-deficient (CCR6–/–) mice were originally generated in
Dr. Lira's laboratory and were subsequently backcrossed eight
generations onto a C57BL/6 background [17, 24]. Mice were
housed in the animal care facility at the University of Michigan.
The University Committee on Use and Care of Animal
(UCUCA) at the University of Michigan approved all experi-
mental procedures.
Experimental sepsis induced by CLP
CLP surgery was performed on mice as previously described
[52]. In brief, mice were anesthetized with an i.p. injection of
2.25 mg of ketamine HCL (Abbott Laboratories, Chicago, IL)
and 150 lg of xylazine (Lloyd Laboratories, Shenandoah, IA).
Under sterile surgical conditions, a 1-cm midline incision was
made to the ventral surface of the abdomen, and the cecum
was exposed. The cecum was partially ligated at its base with a
3.0 silk suture and punctured nine times with 21-gauge needle.
The cecum was returned to the peritoneal cavity, and the
abdominal incision was closed using surgical staples. Mice
were rehydrated with 1 mL saline s.c. and placed on a heating
pad until they recovered from anesthetic. At 4, 24 and 72 h
after surgery, CLP mice were anesthetized and bled. Peritoneal
lavage was performed with 2 mL of cold sterile saline. Serum
and cell-free peritoneal fluid were collected for chemokine/
cytokine protein analyses. RBC were lysed in ammonium
chloride buffer (150 mM NH4CL, 10 mM NaHCO3, 1 mM
EDTA- tetrasodium), and the total cell numbers were
determined using a hemocytometer. Cytospins (Shandon,
Waltham, MA) were prepared and stained with Diff-Quik
solutions (Dade Behring, Dudingen, Switzerland). The leuko-
cyte composition was analyzed, and the percentage of PMN
and mononuclear cells was multiplied by the total cell count to
determine their absolute number.
Survival studies following CLP
The first set of survival studies was performed to determine the
effect of the presence of CCR6 on survival in CLP-induced
sepsis animal model. WT and CCR6–/– mice were subjected to
CLP surgery in the presence or absence of the treatment with
antibiotic INVANZ (Ertapenem) i.p. injected at 75 mg/kg
(Merck & Co, Whitehouse station, NJ) 6 h after surgery and
every 24 h until day 3 post-CLP. Survival was monitored for
6 days following surgery. The second set of survival studies
focused on the role of endogenous CCL20 following induction
of acute septic peritonitis. WT mice were i.p. injected with
20 lg/per mouse of anti-mouse CCL20 mAb (R&D systems,
Rochester, MN) 2 h before CLP and every day following
surgery to block endogenous CCL20. Rat IgG1 was used as a
control. Survival was monitored for 6 days following surgery.
Flow cytometry analysis
Total peritoneal cells were harvested by peritoneal lavage with
10 mL cold sterile saline twice from nave WTor CCR6–/– mice
or at indicated time points following CLP. After lysing RBCwith
ammonium chloride buffer, total cell numbers were deter-
mined using a hemocytometer. Fc binding was blocked via a
10 min incubation with purified rat anti-mouse CD16/CD32
(FccIII/II receptor). Then, the cells were stained with the
following mAb to identify series of mouse cell types: PE-
conjugated anti-CD11b in combination with FITC-conjugated
anti-F4/80 (macrophage), FITC-anti-CD19 (B cell), PE-anti-I-
Ab in combination with FITC-anti-CD11c (DC), PE-anti-NK1.1
(NK cell), PE-anti-CD4 in combination with FITC-anti-CD8
(CD4+ and CD8+ T cell). The appropriate IgG isotypes were
used as controls. All antibodies and IgG isotypes were
purchased from BD PharMingen (San Diego, CA), except for
anti-F4/80 (Serotec, Raleigh, NC). The cells were fixed in 1%
paraformaldehyde and kept in the dark at 4C until analysis
with a FACSCaliber (CELLQuestTM software; Becton Dick-
inson, Mountain View, CA).
Peritoneal macrophage collection and in vitro
stimulation
Total peritoneal cells were harvested by peritoneal lavage with
10 mL cold sterile saline twice from WT or CCR6–/– mice in
nave status or at day 3 post-CLP. Lavage was pooled for mice
in the same group. RBC were lysed in ammonium chloride
buffer. The remaining cells were thoroughly washed with
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saline and counted in a hemocytometer. Cytospins were
prepared and stained with Diff-Quik solutions, and the number
of peritoneal macrophages was determined. Cells were
resuspended at a concentration of 106 macrophages/mL in
RPMI 1640 (BioWhittaker, Walkersville, MD) supplemented
with 5% FCS, 2 mM L-glutamine, 100 U/mL penicillin, and
100 lg streptomycin. Macrophages were plated in plastic 48-
well cell culture plate (4105/well) (Corning, Acton, MA) and
incubated 2 h at 37C in 5% CO2. Nonadherent cells were
removed, and adherent cells were washed with complete RPMI
1640 medium, followed by the stimulation with 1 lg/mL LPS
(Sigma-Aldrich, St. Louis, MO). Four hours later, total RNA
was isolated from cultured peritoneal macrophages using
Trizol reagent and quantitative real-time PCR (TaqMan) was
performed to measure cytokine/chemokine gene expression.
Twenty-four hours later, cell-free supernatant from each
sample was collected and stored in –80C until cytokine/
chemokine protein assay by ELISA. For the LPS rechallenge
experiments, isolated peritoneal macrophages were pretreated
with 10 ng/mL LPS for 24 h, washed twice and then exposed
to a second challenge with 1lg/mL LPS. Twenty-four hours
later, the supernatants were collected to measure cytokine
protein levels by ELISA.
RNA isolation and real-time PCR (TaqMan)
Total RNA was isolated from cultured peritoneal macrophages
using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer's directions. A total of 2.0 lg of RNAwas reverse
transcribed to yield cDNA in a 25 lL reaction mixture
containing 1X first strand (Life Technologies, Gaithersburg,
MD), 250 ng of oligo (dT)12–18 primer, 1.6 mM dNTP
(Invitrogen), 5 U of RNase inhibitor (Invitrogen), and 100 U
of Moloney murine leukemia virus reverse transcriptase
(Invitrogen). Complementary DNA was then analyzed by
quantitative, real-time PCR using a TaqMan 7500 sequence
detection system (Applied Biosystems). GAPDH was analyzed
as an internal control. The fold differences inmRNA expression
between treatment groups were determined by the Sequence
Detection Systems software (Applied Biosystems).
ELISA
Concentrations of IL-10, IL-12p70, TNF-a, CCL2, CCL3,
CXCL10 were measured in cell-free peritoneal lavage fluid,
serum, and cell culture supernatants using a standardized
sandwich ELISA technique as previously described in detail
[17, 53]. Briefly, C96 Maxisorp Nunc-Immuno plates (Fisher
Scientific) were coated with 1–5 lg/mL capture Ab in coating
buffer overnight at 4C and washed with PBS containing
0.05% Tween 20. All Ab used for ELISA were purchased from
R&D Systems. Nonspecific binding sites were blocked with 2%
BSA in PBS for 90 min at 37C. Plates were rinsed four times
with wash buffer and cell-free supernatants were loaded and
incubated for 1 h at 37C. After four washings, a biotinylated
detection polyclonal Ab was added for 45 min at 37C. The
plates were washed again and peroxidase-conjugated strepta-
vidin (Bio-Rad) was added to the well for 30 min at 37C.
Plates were washed, and after the addition of chromogen
substrate (Bio-Rad), OD readings were measured at 490 nm
using an ELISA plate reader. Recombinant murine cytokines
were used to generate the standard curves from which the
concentrations present in the samples were calculated. The
limit of detection of the assays was 50 pg/mL.
Nitrite production
Nitrite (NO2
–) levels were determined using the Griess method
as previously described [54]. The measurement of this
parameter is widely accepted as indicative of NO production.
Briefly, nave peritoneal macrophages were plated at 4  105/
well of a 96-well cell culture plate (Corning) and rested
overnight. Cells were treated with fresh complete RPMI 1640
medium alone, 20 U/mL IFN-c (PeproTech), 100 ng/mL LPS,
or both IFN-c and LPS. After 48 h at 37C in 5% CO2, 50 lL of
cell-free supernatants was transferred to a flat-bottom 96-well
plate and treated with 100 lL of 0.5% sulfanilamide (Sigma-
Aldrich) and 0.05% naphthylethylenediamine dihydrochloride
(Sigma-Aldrich) in 2.5% phosphoric acid (H3PO4). The
absorbance was read at 550 nm in a microplate reader. A
standard curve was generated using known concentrations of
NaNO2 (Sigma-Aldrich). Similar results were shown in three
independent experiments.
Statistics
Statistical analysis was carried out with Prism 4 for Macintosh.
In survival studies a log-rank test was used to test for
significance. For all other studies results are presented as the
mean  SEM, and unpaired Student's t-test was applied to
evaluate significance. Values of p <0.05 were considered
statistically significant.
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